What radiologically isolated syndrome is
MRI scans are ordered for headaches, dizziness, head injuries, and sinus problems every day, and a small number of them show something the scan was not looking for: lesions in the white matter that have the size, shape, and location typical of multiple sclerosis, in a person who has never had a symptom of MS. That finding is called radiologically isolated syndrome, or RIS. It was first defined in 2009, once MRI had become common enough for the situation to arise regularly.
RIS is not a diagnosis of MS, and it is not a reassurance either. It describes the earliest stage at which the disease process can be seen: demyelination is happening, but it has not yet touched a pathway that produces a symptom. The clinically isolated syndrome is the next stage, when a first symptom arrives. Which people move from one to the other, and how quickly, is now reasonably well understood.
Visual guide
What makes a lesion MS-typical
- Location: Beside the fluid spaces, under the cortex, in the brainstem or cerebellum, or in the spinal cord.
- Shape: Oval lesions oriented at right angles to the ventricles, sometimes with a central vein.
- Not RIS: Small scattered spots from migraine, small vessel disease, or age, which sit elsewhere and look different.
RIS or ordinary white spots?
Most white matter lesions on MRI are not MS and not RIS. Migraine, high blood pressure, diabetes, smoking, and age all produce small scattered spots, usually deep in the white matter and away from the ventricles. RIS requires lesions that meet the same MRI criteria for location used to diagnose MS: beside the ventricles, just under the cortex, in the brainstem or cerebellum, or in the spinal cord, with the oval shape and orientation MS produces. Many radiology reports use the phrase "nonspecific" for spots that do not meet that bar, and that word is doing real work. Reading the images directly, rather than relying on the report, is the first step in deciding which situation you are in.
The risk of developing MS
The long-term studies of RIS give consistent numbers. About a third of people have a first symptom within five years, and about half within ten. Several findings raise the risk, and they are the ones a specialist looks for:
- A lesion in the spinal cord, the strongest single predictor.
- Younger age, under about 37, at the time the scan was done.
- Abnormal spinal fluid: oligoclonal bands or elevated kappa free light chains.
- Enhancing lesions on a contrast scan, meaning active inflammation now.
- New lesions on a follow-up scan.
- Male sex, and a larger number of lesions.
The 2024 McDonald criteria took the further step of allowing MS to be diagnosed in some people with RIS: when there are typical lesions in at least two of the five characteristic locations plus either new or enhancing lesions over time, abnormal spinal fluid, or a scan showing the central vein sign. For those people, the disease is considered established, and the question becomes treatment rather than monitoring.
How RIS is evaluated
A specialist review of RIS has a defined shape. The images themselves are reviewed, not just the report, to confirm the lesions are genuinely MS-typical. A careful history often turns up an episode years earlier, such as a few weeks of blurred vision or numbness, that was never evaluated and would change the label from RIS to a past attack. The examination looks for signs that never registered as symptoms. Then the workup is completed: MRI of the full spinal cord if it has not been done, a contrast brain scan, blood tests to exclude conditions that mimic MS, and usually a lumbar puncture, because the spinal fluid result changes both the risk estimate and, under the new criteria, possibly the diagnosis. The MS evaluation here covers all of it in one visit.
Monitoring and treatment
For years the only plan for RIS was to watch. Two randomized trials published in 2023 changed that: in people with RIS, both dimethyl fumarate and teriflunomide substantially reduced the chance of a first clinical event over about two years compared with placebo. Treatment before symptoms is therefore an option with evidence behind it, not a theoretical one.
It is not automatic. For someone with few lesions, a normal spinal cord, and normal spinal fluid, the risk is low enough that monitoring with a repeat MRI in six to twelve months is a sound plan. For someone with a spinal cord lesion, abnormal spinal fluid, or new lesions on follow-up, the case for starting a disease-modifying therapy is strong, and if the 2024 criteria are met the diagnosis is MS and treatment is standard care. In between, the decision is made together, with the numbers on the table.
Visual guide
Monitoring RIS over time
- Baseline: Brain and spinal cord MRI, spinal fluid, and blood tests set the starting point.
- Follow-up: Repeat MRI at intervals looks for new lesions, which raise the risk and may confirm MS.
- Decision: Findings, age, and your own priorities decide between monitoring and starting treatment.
When to see a neurologist
See an MS specialist if an MRI report mentions demyelination, lesions "concerning for" or "in a pattern suggestive of" MS, or periventricular or juxtacortical lesions, even when you feel entirely well and even if a radiologist or another physician suggested simply repeating the scan in a year. The review is not about alarm; it is about getting the risk estimate right and choosing a plan on purpose. At our Multiple Sclerosis Clinic, Dr. Ntranos, a fellowship-trained MS specialist, reads your images with you scan by scan in a 60-minute visit, usually the same or next day, in Beverly Hills, West Los Angeles, or by video anywhere in California. Bring or upload the actual images, not only the report, through our patient tools page.
Frequently asked questions
References
- Okuda DT, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One, 2014.
- Okuda DT, et al. Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome (ARISE). Annals of Neurology, 2023.
- Lebrun-Frénay C, et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome (TERIS). JAMA Neurology, 2023.
- Montalban X, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. The Lancet Neurology, 2025.
- National Institute of Neurological Disorders and Stroke. Multiple sclerosis.